Sinovac Life Sciences Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING3
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Sinovac PCV13 NCT06617715 |
P3 | Recruiting | Pneumococcal Infectious Disease | 3080 | 2026-05-12 (+14 mo) |
| Oral hexavalent reassortant rotavirus attenuated live vaccine NCT06967272 |
P2 | Recruiting | Rotavirus Gastroenteritis | 400 | 2026-06-15 |
| Sinovac PCV24 NCT07300644 |
P2 | Recruiting | Pneumococcal Infectious Disease | 420 | 2026-09 |
| Sinovac PCV13 lot 1 NCT07832500 |
P3 | Not yet recruiting | Pneumococcal Infectious Diseases | 1125 | 2027-03 |
| SNA02-48 NCT07633119 |
P3 | Not yet recruiting | Tetanus | 600 | 2027-03-31 |
| Sinovac PCV13 NCT07593924 |
P3 | Not yet recruiting | Pneumococcal Infectious Diseases | 500 | 2027-07 |